- Home
- PINC vs SUPN Comparison
PINC vs SUPN Comparison
Compare PINC & SUPN Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- PINC
- SUPN
- Stock Information
- Founded
- PINC 2013
- SUPN 2005
- Country
- PINC United States
- SUPN United States
- Employees
- PINC N/A
- SUPN N/A
- Industry
- PINC Other Consumer Services
- SUPN Biotechnology: Pharmaceutical Preparations
- Sector
- PINC Consumer Discretionary
- SUPN Health Care
- Exchange
- PINC Nasdaq
- SUPN Nasdaq
- Market Cap
- PINC 1.9B
- SUPN 1.9B
- IPO Year
- PINC 2013
- SUPN 2012
- Fundamental
- Price
- PINC $21.30
- SUPN $36.43
- Analyst Decision
- PINC Hold
- SUPN Hold
- Analyst Count
- PINC 7
- SUPN 1
- Target Price
- PINC $21.42
- SUPN $36.00
- AVG Volume (30 Days)
- PINC 1.1M
- SUPN 348.4K
- Earning Date
- PINC 02-03-2025
- SUPN 02-25-2025
- Dividend Yield
- PINC 3.94%
- SUPN N/A
- EPS Growth
- PINC N/A
- SUPN 130.79
- EPS
- PINC 1.32
- SUPN 1.07
- Revenue
- PINC $1,325,477,000.00
- SUPN $651,972,000.00
- Revenue This Year
- PINC N/A
- SUPN $7.82
- Revenue Next Year
- PINC $1.78
- SUPN N/A
- P/E Ratio
- PINC $16.16
- SUPN $34.05
- Revenue Growth
- PINC 2.65
- SUPN 6.79
- 52 Week Low
- PINC $17.96
- SUPN $25.53
- 52 Week High
- PINC $23.56
- SUPN $39.37
- Technical
- Relative Strength Index (RSI)
- PINC 41.40
- SUPN 52.26
- Support Level
- PINC $20.96
- SUPN $35.73
- Resistance Level
- PINC $21.98
- SUPN $37.34
- Average True Range (ATR)
- PINC 0.49
- SUPN 1.20
- MACD
- PINC -0.06
- SUPN -0.01
- Stochastic Oscillator
- PINC 19.56
- SUPN 69.02
About PINC Premier Inc.
Premier Inc is a Charlotte, North Carolina-based technology-driven healthcare improvement company, uniting an alliance of United States (U.S.) hospitals, health systems, and other providers and organizations to transform healthcare. The company's revenue is all sourced domestically and is reported in two business segments: the supply chain services and the consulting and technology platform of performance services. It generates the majority of its revenue from the supply chain services segment.
About SUPN Supernus Pharmaceuticals Inc.
Supernus Pharmaceuticals Inc is a specialty pharmaceutical company. The company is engaged in developing and commercializing products for the treatment of central nervous system diseases, including neurological and psychiatric disorders. The Company's diverse neuroscience portfolio includes approved treatments for epilepsy, migraine, attention-deficit hyperactivity disorder (ADHD), hypomobility in Parkinson's Disease (PD), cervical dystonia, chronic sialorrhea, dyskinesia in PD patients receiving levodopa-based therapy, and drug-induced extrapyramidal reactions in adult patients. The company products include Trokendi XR, Oxtellar XR, Qelbree, APOKYN, XADAGO, MYOBLOC, GOCOVRI, and Osmolex ER.